Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 10/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.34 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29188244 | 1.00 | HCAR3 (0.42) | HCAR3L3MBTL1KDM4EGLAHTT | |
| SCHEMBL29188208 | 0.94 | HCAR3 (0.44) | HCAR3L3MBTL1KDM4EGLAHTT | |
| SCHEMBL30801012 | 0.94 | HCAR3 (0.44) | HCAR3L3MBTL1KDM4EGLAHTT | |
| SCHEMBL29188212 | 0.89 | HCAR3 (0.35) | HCAR3L3MBTL1KDM4EGLAHTT | |
| SCHEMBL31233650 | 0.89 | HCAR3 (0.35) | HCAR3L3MBTL1KDM4EGLAHTT | |
| SCHEMBL30801017 | 0.84 | DHODH (0.36) | L3MBTL1KDM4EGLAHTTKMT2A | |
| SCHEMBL29188261 | 0.84 | DHODH (0.36) | L3MBTL1KDM4EGLAHTTKMT2A | |
| SCHEMBL29188263 | 0.84 | DHODH (0.36) | L3MBTL1KDM4EGLAHTTKMT2A | |
| SCHEMBL30801016 | 0.84 | DHODH (0.36) | L3MBTL1KDM4EGLAHTTKMT2A | |
| SCHEMBL31233476 | 0.84 | OPRK1 (0.40) | HCAR3DHODHEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327385-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | LIANG GUIBAI (US) | 2024-10-03 | — | — | US | disclosed |
| CN-117865941-A | Substituted piperidine compounds, process for their preparation and their use | 上海方予健康医药科技有限公司 | 2024-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327385-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | REN, ACE, AGTR1 | HCAR3 2198/4885L3MBTL1 4881/4885KDM4E 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.